Serum of Interferon Lambda-1 level as a protein biomarker for the diagnosis of COVID-19 severity Cover

.blurhash-client-img { display: none !important; }

Serum of Interferon Lambda-1 level as a protein biomarker for the diagnosis of COVID-19 severity

Current Issues in Pharmacy and Medical Sciences

Volume 37 (2024): Issue 4 (December 2024)

By: Shakir Abdulridha Abbas , Hanaa Addai Ali , Rawaa Adday Ali , Muthanna Saleh Mashkur , Mohammed Saeed Salman Hasan , Ayat Saeed Awad and Mohauman Mohammed Al Rufaie

Open Access

|Nov 2024

Authors

Shakir Abdulridha Abbas

Department of Chemistry, Faculty of Science, University of Kufa, Najaf, Iraq

Hanaa Addai Ali

Department of Chemistry, Faculty of Science, University of Kufa, Najaf, Iraq

Rawaa Adday Ali

Microbiology Department, College for of Veterinary Medicine, Al-Qasim Green University, Babylon, Iraq

Muthanna Saleh Mashkur

Department of Chemistry, Faculty of Science, University of Kufa, Najaf, Iraq

Mohammed Saeed Salman Hasan

AL-Sadr Medical City, Najaf, Iraq

Ayat Saeed Awad

Department of Chemistry, Faculty of Science, University of Kufa, Najaf, Iraq

Mohauman Mohammed Al Rufaie

muhaimim.alrufaie@uokufa.edu.iq

Department of Chemistry, Faculty of Science, University of Kufa, Najaf, Iraq

DOI: https://doi.org/10.2478/cipms-2024-0033 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X

Journal RSS Feed

Language: English

Page range: 200 - 207

Submitted on: May 8, 2023

|

Accepted on: Jul 30, 2023

|

Published on: Nov 28, 2024

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

severe COVID-19,

Interferon Lambda-1 (IFN-λ1)

Related subjects:

Clinical medicine,

Clinical medicine, other,

Pharmacology, toxicology,

Pharmacy, other

© 2024 Shakir Abdulridha Abbas, Hanaa Addai Ali, Rawaa Adday Ali, Muthanna Saleh Mashkur, Mohammed Saeed Salman Hasan, Ayat Saeed Awad, Mohauman Mohammed Al Rufaie, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous article Volume 37 (2024): Issue 4 (December 2024)Next article